Amendments to the Claims

The below listing of claims is intended to replace all prior versions of the claims in the application.

1. (Currently Amended) A benzisothiazole-3(2H)-one compound of formula (I)



(I)

wherein;

R_1 is the group ~~(C_5-C_{12})alkyl~~ (C_5-C_7)alkyl,, (C_4-C_{12})haloalkyl, (C_4-C_{12})alkenyl, (C_4-C_{12})alkynyl, (C_1-C_8)alkylcycloalkyl, (C_3-C_8)cycloalkyl, (C_1-C_{12})alkylheterocyclic radical, (C_3-C_4)alkylaryl, or aryl wherein the aryl or ~~heterocyclkic~~ heterocyclic group is ~~optionally~~ substituted with ~~one 1 to~~ 2 or 3 groups independently selected from (C_1-C_{12})alkyl, (C_2-C_{12})alkenyl, (C_1-C_{12})alkoxy, (C1-C8)alkylcycloalkyl, ~~halo,~~ and (C_1-C_{12})haloalkyl;

R_2 is hydrogen;

R_3, R_4, R_5, and R_6, are each independently selected from hydrogen, (C_2-C_{12})alkyl, (C_1-C_{12})haloalkyl, (C_1-C_{12})alkoxyalkyl, (C_1-C_{10})thioalkyl, hydroxy, (C_2-C_{12})alkenyl, (C_2-C_{12})alkynyl, (C_1-C_{12})alkylaryl, (C_1-C_{12})alkylcycloalkyl, (C_1-C_{12})alkylheterocyclic, C(O)C_1-C_6 alkyl, C(O)OC_1-C_6alkyl, phenyl or aryl; wherein each of alkyl, alkenyl, phenyl or aryl groups may be optionally substituted with one to three substitutents selected from halo, amino, halo, C_1-C_6 alkyl, ~~(C_2-C_6)alkennyl~~ (C_2-C_6)alkenyl, (C_1-C_6)haloalkyl; or a pharmaceutically acceptable salt, solvate or isomer thereof.

2. (Canceled)

3. (Currently Amended) A compound according to Claim 1 wherein R_1, is ~~$(C_5$-$C_8)$alkyl~~ $(C_5$-$C_7)$alkyl, $(C_4$-$C_6)$alkenyl, -O-$(C_1$-C_3 alkyl), $(C_3$-$C_4)$alkylcycloalkyl, -CF_3, or aryl.

4. (Currently Amended) A compound according to Claim 1 wherein R_1, is benzyl substituted with ~~0, 1 or~~ 2 substitutents selected from $(C_1$-$C_6)$alkyl, $(C_2$-$C_4)$alkenyl, -O-$(C_1$-C_3 alkyl), $(C_1$-$C_4)$alkylcycloalkyl, and -CF_3,

5. (Original) A compound of Claim 1 wherein R_3, R_4, R_5 and R_6 are independently selected from the group consisting of $(C_1$-$C_4)$alkyl, $(C_2$-$C_4)$alkenyl, -O-$(C_1$-C_3 alkyl), -S-$(C_1$-C_3 alkyl), $(C_5$-$C_{12})$cycloalkyl, COOH, C(O)$(C_1$-C_3 alkyl), C(O)O$(C_1$-C_3 alkyl), -CF_3, and halo.

6. (Original) The compound of Claim 1 wherein R_5 is the group represented by COOH, C(O)$(C_1$-C_3 alkyl), C(O)O$(C_1$-C_3 alkyl), chloro, bromo or CF_3.

7. (Currently Amended) A compound of formula (I)



(I)

wherein R_1 through R_6 are selected to provide a compound selected from the group consisting of:

~~3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid ethylamide;~~

~~3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid propylamide;~~

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid allylamide;

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid pentylamide;

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid hexylamide;

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (5-methyl-hexyl)-amide;

~~3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid dodecylamide;~~

~~3~~-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid cyclohexylamide;

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid 2-methyl-benzylamide;

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid 3-methyl-benzylamide;

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid 4-methyl-benzylamide;

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid 2-ethyl-6-methyl-benzylamide;

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid 2-isopropyl-6-methyl-benzylamide;

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid phenethylamide;

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (2-thiophen-2-yl-ethyl)-amide;

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (3-phenyl-propyl)-amide;

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (4-phenyl-butyl)-amide;

3-Oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid (4-cyclohexyl-butyl)-amide;

5-Methyl-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid butylamide;

6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid propylamide;

6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid isopropylamide;

6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid butylamide;

6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid hexylamide;

6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid cyclohexylamide; and

~~6-Chloro-3-oxo-3*H*-benzo[*d*]isothiazole-2-carboxylic acid benzylamide.~~

8. (Original) A benzisothiazole-3(2H)-one compound represented by the formulae (C1), (C2), (C3), or (C4):



(C1),



(C2),



(C3),



(C4).

9. (Original) A pharmaceutical formulation comprising a benzisothiazole-3(2H)-one compound of formula I together with a pharmaceutically acceptable carrier or diluent.

10. (Currently Amended) A method of inhibiting hepatic lipase and/or endothelial lipase activity using a therapeutically effective amount of benzisothiazole-3(2H)-one compound of formula I, wherein R_1-R_6 are as defined in claim 1



I

or a pharmaceutical acceptable salt, solvate, or prodrug thereof.

11. (Original) A method of treating a mammal to alleviate the pathological effects of elevated hepatic lipase and/or endothelial lipase activity; comprising administering to said mammal a therapeutically effective amount of a benzisothiazole-3(2H)-one compound according to Claim 1.

12. (Currently Amended) A pharmaceutical formulation containing a therapeutically effective amount of the compound of formula 1, wherein R_1-R_6 are defined as in claim 1



I

~~useful~~ formulated for the treatment and/or amelioration of the effect of elevated hepatic lipase and/or endothelial lipase activity.

13-15. (Canceled)

16. (New) The method of claim 10 wherein the benzisothiazole-3(2H)-one compound is formulated with a with a pharmaceutically acceptable carrier or diluent.

17, (New) The method of claim 11 wherein the benzisothiazole-3(2H)-one compound is formulated with a with a pharmaceutically acceptable carrier or diluent.